Novavax (NVAX) was asked by the US Food and Drug Administration to run an additional randomized clinical trial on its COVID-19 vaccine, The Wall Street Journal reported Friday, citing people familiar with the matter.
That may cost the company tens of millions of dollars, vaccine experts said, according to the report.
The vaccine had showed 90% efficacy in a 30,000-person, placebo-controlled trial, the report said.
The FDA request allows the company to negotiate for a smaller, less expensive study, the report said, citing a person familiar with the matter.
The Department of Health and Human Services and Novavax didn't immediately respond to requests for comment from MT Newswires.
Novavax shares fell 1.4% in after-hours trading after dropping 5.7% in the regular session.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.